Eftozanermin alfa (ABBV-621)是一种由变异型免疫球蛋白G1-Fc与两个单链三聚体肿瘤坏死因子相关凋亡诱导配体(TRAIL)组成的融合蛋白。作为肿瘤坏死因子相关凋亡诱导配体受体(TRAIL-R)激动剂,它能够通过激活死亡受体（DR4 receptor和DR5 receptor）来诱导肿瘤细胞凋亡(apoptosis)。该化合物可用于多种实体瘤和血液肿瘤的研究。
[1] Phillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, Tahir SK, Smith ML, Zhang H, Widomski D, Abraham VC, Xu N, Liu Z, Zhou L, DiGiammarino E, Lu X, Rudra-Ganguly N, Trela B, Morgan-Lappe SE. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors. Cancer Res. 2021 Jun 15,81(12):3402-3414. doi: 10.1158/0008-5472.CAN-20-2178. Epub 2021 Mar 9. PMID: 33687950.[2]Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023 Apr 27,141(17):2114-2126. doi: 10.1182/blood.2022017333. PMID: 36720090, PMCID: PMC10646782.
